3rd Quarter - Report

IKARIA for IKARIA

Firm
Client
Income
—
Expenses
$130,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Manufacturing MAN

Pharmaceutical pedigree anti-counterfeiting proposals (S959/HR 1919)

LobbyistCovered position, as disclosed
ANNE ELIZABETH ESPOSITO —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 1919 (113th)

Medical/Disease Research/Clinical Labs MED

Funding for rare disease research

LobbyistCovered position, as disclosed
ANNE ELIZABETH ESPOSITO —
LEAH DUFFY SVOBODA New —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Budget/Appropriations BUD

Deficit reduction/impact of sequestration on FDA and NIH; Food and Drug Administration Safety Over Sequestration Act of 2013 (HR 2725); FDA User Fee Protection Act (S 1413)

LobbyistCovered position, as disclosed
ANNE ELIZABETH ESPOSITO —
LEAH DUFFY SVOBODA New —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 2725 (113th)

Health Issues HCR

340B Drug Pricing Program; Critical Care; Critical Care Assessment and Improvement Act of 2013 (HR 2651).

LobbyistCovered position, as disclosed
ANNE ELIZABETH ESPOSITO —
LEAH DUFFY SVOBODA New —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 2651 (113th)

Medicare/Medicaid MMM

Non-interference; rebates; Protecting Seniors' Access to Medicare Act of 2013 (S 351 and HR 351)

LobbyistCovered position, as disclosed
ANNE ELIZABETH ESPOSITO —
LEAH DUFFY SVOBODA New —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 351 (113th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.